AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.1 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese | Open Access

Degradable esophageal stent based on PCL/PLGA blend: degradation rate regulation and in vitro performance analysis

Wenxin CAO1, Genpang WANG2, Chong SHEN1, Zhulun ZHUANG1, Kaihong WU1 ( ), Jian SUN1 ( )
Department of Cardiothoracic Surgery, the Affiated Children’s Hospital of Nanjing Medical University, Nanjing 210008
Nanjing Yirongda Intelligent Medical Additive Manufacturing Research Institute, Nanjing 211166, China
Show Author Information

Abstract

Objective

This study aimed to develop a biodegradable esophageal stent based on polycaprolactone (PCL) blended with poly (lactic-co-glycolic acid) (PLGA), achieving controllable degradation rates by adjusting the PLGA ratio (0%-35%), balancing mechanical properties and degradation cycles, and exploring its in vitro degradation characteristics and clinical adaptation potential.

Methods

PCL and PLGA were selected to prepare eight gradient blend ratios (0%, 5%, 10%, 15%, 20%, 25%, 30%, 35% PLGA) by extrusion-based high-temperature melt rotary 3D printing technology, combined with a honeycomb porous structure design (porosity 60%-70%). In vitro degradation experiments lasting 8 weeks were conducted using artificial saliva (pH≈6.6) and artificial gastric juice (pH≈4.0).

Results

The PLGA ratio significantly affected the degradation rate, with increasing PLGA proportion accelerating stent degradation. The blending of PLGA and PCL produced a synergistic effect (for every 10% increase in PLGA, the time to reach the same weight loss rate was shortened by approximately 50%-70%), leading to stage-wise disintegration phenomena (when PLGA≥25%). The pH difference had no significant impact on degradation (P > 0.05), possibly due to the high-porosity design promoting diffusion of acidic products and the hydrophobic balance of PCL. Through ratio adjustment, degradation cycles of 4-24 weeks could be achieved.

Conclusion

The PCL/PLGA blend stent achieves precise control of degradation rate through simple ratio adjustment, producing a unique“support-disintegration”mode that reduces residual risks and meets clinical needs ranging from congenital strictures to acute inflammation. In addition, the combination of 3D printing technology with biomimetic morphology and porous structure design significantly improves tissue conformity and anti-migration properties of the stent. This study provides theoretical basis and technical support for personalized biodegradable esophageal stent therapy.

CLC number: R318.08; R571 Document code: A Article ID: 1007-4368(2026)06-832-08

References

【1】
【1】
 
 
Journal of Nanjing Medical University (Natural Sciences)
Pages 832-839

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
CAO W, WANG G, SHEN C, et al. Degradable esophageal stent based on PCL/PLGA blend: degradation rate regulation and in vitro performance analysis. Journal of Nanjing Medical University (Natural Sciences), 2026, 46(6): 832-839. https://doi.org/10.7655/NYDXBNSN251068

2

Views

0

Downloads

0

Crossref

Received: 27 September 2025
Revised: 08 April 2026
Accepted: 18 April 2026
Published: 15 June 2026
© 2026 Editorial Board of Journal of Nanjing Medical University(Natural Sciences)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).